MI 13:00 – 15:00 Satellitenveranstaltung
Neue Perspektiven in der Pathophysiologie und Behandlung bipolarer Störungen
H. Grunze (München)
Ionenkanäle und bipolare Störungen

N. Michael (Münster)
Glutamaterge Imbalancen bei bipolaren Störungen

J. Walden (Freiburg)
Neue Strategien in der Therapie der akuten bipolaren Manie

K: Erfurth (Münster)
Neue Strategien in der Therapie der akuten bipolaren Depression

Gesponsert durch die Firma Lilly Deutschland GmbH

MI 15:30 – 17:30 Satellitenveranstaltung
Erfahrungen aus 10 Jahren Johanniskraut-Forschung – Ist ein Paradigmenwechsel notwendig?
H. Murck (Berlin)
Depression differenziert – Neurobiologie und Klinik

U. Hemmeter (Marburg)
Schlaf-endokrinologische Effekte von Johanniskraut bei depressiven Patienten

W.-E. Müller (Frankfurt/Main)
Mechanismen von Johanniskraut auf zellulärer Ebene – neue Befunde

H.-P. Volz (Werneck)
Somatisierung, Fatigue, Depression – Indikationen für Johanniskraut?

Gesponsert durch die Firma Lilly Deutschland GmbH

DO 8:45 – 10:30 Symposium I Raum A

J. Wiltfang (Göttingen)
Amino- and carboxyterminal modified Ab peptides: Relevance for the diagnosis and pathophysiology of Alzheimer’s disease

DO 8:45 – 10:30 Symposium II Raum C

S. Herpertz (Aachen)
Impulsivity in personality disorders

K.L. Lesch (Würzburg)
Impulsivity, aggression, and serotonin: a molecular psychobiological perspective

G. Juckel (München)
Loudness dependence of auditory evoked potentials as indicator of both central serotonergic function and impulsivity

DO 8:45 – 10:30 Symposium III Raum D

U. Voderholzer (Freiburg)
Chronobiological therapies for affective disorders: State of the art

K. Lieb (Freiburg)
Substance-P-receptor antagonists- a new strategy of antidepressant and anxiolytic pharmacotherapy

P. Falkai (Bonn)
Vagusnerve stimulation: An option in treatment resistant depression?

H. Künzel (München)
CRH-receptor antagonists as possible new antidepressive drugs

F. Padberg (München)
TMS for the treatment of affective disorders: news from recent studies

DO 11:00 – 12:45 Symposium IV Raum A

M. Deuschle (Mannheim)
Visceral obesity and plasma leptin in depressed patients

F.M. Theisen (Marburg)
Antipsychotic-induced body weight gain: Epidemiological, regulatory and genetic aspects

T. Wetterling (Frankfurt)
Influence of neuroleptics on body weight

DO 11:00 – 12:45 Symposium V Raum D

R. Demmel (Münster)
Reactivity to alcohol cues: The impact of stimulus intensity and other experimental factors

A.J. Fallgatter (Würzburg)
Electrophysiological cue-reactivity in alcoholism

F. Schneider (Düsseldorf)
Cue induced-craving before and after therapy in alcoholic patients: an fMRI study

A. Heinz (Mannheim)
Brain imaging studies on cue-reactivity in alcoholism

A. Szegedi (Mainz)
Cue reactivity as a predictor of response to cue exposure treatment: results from the NeVeR study

DO 11:00 – 12:45 Symposium VI Raum C

M. Lanczik (Erlangen)
Gender differences in the psychopharmacological treatment

A. Bergant (Innsbruck)
Pharmacological treatment of premenstrual dysphoric disorder

P. Britsch (Berlin)
Psychopharmacotherapy during pregnancy and lactation

C. Klier (Wien)
St. John’s Wort (hypericum perforatum) – is it safe while breastfeeding?

N. Bergemann (Heidelberg)
Estrogen as a therapeutic strategy in mental disorders

1. A. Dittmann-Balcar¹, S. Bender¹, U. Schall², J. Wolstein¹, A. Klimke³, N.
   Müller⁴, E-U. Vorbach⁵, K-U Kühn⁶, M. Lambert⁷, RW. Dittmann⁸, D. Naber⁷
   (¹Essen, ²Newcastle-Australia, ³Düsseldorf, ⁴ München, ⁵Darmstadt, ⁶Bonn,
   ⁷Hamburg, ⁸Bad Homburg)
   Effects of olanzapine versus clozapine on executive functions in schizophrenia
2. A. Brunnauer, G. Laux, E. Geiger (Wasserburg am Inn)
   Atypical antipsychotics and newer antidepressants: Effects on neuropsychological test performance in schizophrenic and depressive patients
3. J. Cordes, A. Klimke (Düsseldorf)
   Olanzapine-induced reversible neutropenia: two case reports
4. J. Czekalla (Bad Homburg)
   Olanzapine for injection: rapid intramuscular (IM) application for acute treatment and transition to oral ZyprexaÒ
5. RW. Dittmann^1,2, K. Mann³, M. J. Müller³, F. Müller-Siecheneder³, W. Rossbach³, H. Russ², H. Wetzel³, O. Benkert³ (¹Hamburg, ²Bad Homburg, ³Mainz)
   Schizophrenic patients with predominantly positive or negative symptomatology treated with olanzapine: Are there differences in efficacy, safety, quality of life, and psychosocial functioning?
6. G. P. Eckert¹, E. Schaeffer¹, A. Schmitt², A. Maras², WF. Gattaz¹ (¹Sao Paulo, ²Mannheim)
   Membrane alterations in the frontal lobe in schizophrenia
7. G. Gründer, T. Siessmeier, H-G. Buchholz, I. Vernaleken, P. Stoeter, F. Rösch, P. Bartenstein (Mainz)
   Quantification of extrastriatal dopamine receptors in the human brain: a PET study with [¹⁸F]fallypride
8. D. Hubl^1,2, H. Kleinlogel², L. Frölich¹, T. Weinandi¹, K. Maurer¹ , W. Holstein³, J. Czekalla³, T. Dierks^1,2 (¹Frankfurt/Main, ²Bern, ³Bad Homburg)
   Multilead quantitative EEG profile and cognitive evoked potentials (P300) in healthy subjects after a single dose of olanzapine
9. C. Klawe, I. Anghelescu, H. Himmerich, J. Röhrich, A. Szegedi, C. Hiemke (Mainz)
   A case of possible N-benzylpiperazine induced persisting perception disorder and description of initial intoxication syndrome
10. S. Löffler, K. Fehsel, U. Henning, K. Krieger, V. Kolb-Bachofen, A. Klimke (Düsseldorf)
    Coadministration of clozapine and antioxidant: an old new discussion
11. M. J. Müller (Mainz)
    Reliability and validity of a German version of the rating scale for emotional blunting (SEB): Preliminary results
12. F. Pedrosa Gil, O. Dietmaier, H. Waßmuth, M. Ising (München)
    Olanzapine plasma level monitoring in psychiatric patients: concentrations under monotherapy and comedication
13. T. Rammsayer (Göttingen)
    Psychomotor performance as a behavioral indicator of dopaminergic responsivity in healthy human subjects
14. M. J. Schwarz, H. Krönig, M. Riedel, B. Bondy, M. Ackenheil, N. Müller (München)
    Genetic investigations based on immunological findings in schizophrenia
15. R. Thienel¹, S. Bender¹, RD. Oades¹, A. Dittmann-Balcar¹, ML. Rao², U. Schall³ (¹Essen, ²Bonn, ³Newcastle)
    Auditory gating, neuropsychology and D₂-receptor occupancy in an one-year follow-up treatment study on schizophrenia
16. I. Vernaleken¹, T. Siessmeier¹, H-G Buchholz¹, M. Piel¹, P. Stoeter¹, Y. Zhou², DF.Wong², F. Rösch¹, P. Bartenstein¹, G. Gründer¹ (¹Mainz, ²Baltimore-USA)
    PET imaging of D₂-like dopamine receptors in human brain: A comparison of [¹¹C]raclopride and [¹⁸F]desmethoxyfallypride

DO 12:45 – 14:15 Postersitzung I

Schlaf

17. I. A. Antonijevic¹, A. Steiger² (¹Berlin, ² München)
    Depression-like changes of the sleep-EEG during glucocorticoid treatment in patients with multiple sclerosis
18. H. Brunner¹, T. C. Wetter¹, B. E. Högl², C. Trenkwalder¹, A. Yassouridis¹, E. Friess¹ (¹München, ²Innsbruck)
    Microstructure of the sleep EEG in de novo patients with parkinson’s disease: effects of dopamine on the spectral EEG profiles
19. S. Cohrs¹, A. Rodenbeck¹, U. Wortelboer¹, K. Lange^1,2, E. Rüther¹, G. Hajak^1,2 (¹Göttingen, ²Regensburg)
    Gender specific effects of tryptophan depletion on sleep parameters
20. M. Dalal¹, A. Schuld¹, M. Haack¹, M. Uhr¹, P. Geisler², I. Eisensehr¹, S. Noachtar¹, T. Pollmächer¹ (¹München, ²Regensburg)
    Orexin A (hypocretin-1) in narcoleptic patients and control patients
21. W. Jordan¹, H. Tumani², S. Eggert¹, A. Rodenbeck¹, G. Hajak^{1, 3}, E. Rüther¹
    (¹Göttingen, ²Ulm, ³Regensburg)
    Prostaglandin-D-synthase (ß-trace) and melatonin in human healthy sleep
22. A. Schuld, M. Dalal, P. Beitinger, M. Haack, T. Pollmächer (München)
    Alterations in body weight and neuroendocrine systems in human narcolepsy
23. A. Schuld, M. Uhr, T. Pollmächer (München)
    Oligoclonal bands and specific antibody indices in human narcolepsy
24. S. Sorge, T. Pollmächer, M. Lancel (München)
    Effects of clozapine on sleep in rats
25. J. Weikel, K. Held, D. Schmid, M. Ziegenbein, A. Steiger (München)
    Evaluation of the role of somatostatin in age-related changes of sleep-endocrine activity
26. T. C. Wetter, M. Czisch, C. Kaufmann, T. Pollmächer, F. Holsboer, D. P. Auer (München)
    Processing of acoustic stimuli during sleep: A combined fMRI and EEG study
27. M. Ziegenbein, K. Held, H. E. Künzel, H. Murck, I. A. Antonijevic, A. Steiger (München)
    The long acting somatostatin analogue octreotide decreases slow wave sleep in young men
28. U. Hemmeter¹, B. Annen², U. Rose², R. Bischof², U. Brüderlin², M. Hatzinger², E. Holsboer-Trachsler² (¹Marburg, ²Basel)
    Effects of an additional therapy with Ginkgo biloba Extract (Li 1370) on cognitive performance and polysomnography in patients with major depression treated with trimipramine
29. H. Murck, K. Held, M. Ziegenbein, M. Uhr, A. Steiger (München)
    Sleep-endocrine-changes after sleep deprivation in depression – focus on the renin-angiotensin-aldosterone system
30. A. Rodenbeck¹, S. Cohrs¹, U. Wortelboer¹, G. Huether¹, K. Lange^1,2, E. Rüther¹, G. Hajak^1,2 (¹Göttingen, ²Regensburg)
    Interactions between HPA-functions, 5-HT-system and sleep

DO 12:45 – 14:15 Postersitzung I

Angst

31. A. Ströhle, M. Kellner, F. Holsboer, K. Wiedemann (München, Hamburg)
    Panic attacks shift GABAA receptor modulatory neuroactive steroid composition
32. A. Wigger (München)
    Development of two rat lines bred for high (HAB) or low (LAB) anxiety-related behaviour as a novel psychopathological animal model
33. P. Zwanzger, T. C. Baghai, C. Schuele, A. Ströhle, F. Padberg, N. Kathmann, M. Schwarz, H. J. Möller, R. Rupprecht (München)
    Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers

DO 12:45 – 14:15 Postersitzung I

Varia

34. C. J. Fischer, M. R. Lemke, T. Wendorff, G. Fitzer, Z. Rupp, S. Tetzlaff (Kiel)
    A new model for assessment of neuronal mechanisms of behavior control and impulsivity
35. M. Ising (München)
    New developments in Configural Frequency Analysis for the nonparametric assessment of changes in clinical data
36. K. W. Lange, O. Tucha (Regensburg)
    Handwriting and stimulant drug treatment in children with attention deficit hyperactivity disorder
37. M. Schäfer^1,2, F. Schmidt¹, G. Martin¹, M. Soyka¹, R. Lorenz¹, K. Loeschke¹,
    C. Folwaczny¹ (¹München, ²Berlin)
    Are psychiatric disorders or methadone substitution contraindications for the treatment with Interferon-a ? - Results from a prospective controlled study
38. J. Stefanek, H.-J. Kuss, C. Schuessler, U. Hegerl (München)
    Mixed-effects-models in psychiatric longitudinal research

Donnerstag, 27. September 2001

DO 14:15 – 16:00 Freie Vorträge 1 Raum D

Endocrine effects of psychiatric treatments
Vorsitzende: I. Heuser, G. Nikisch

T. Bschor¹, M. Adli¹, C. Baethge¹, U. Eichmann¹, M. Ising², M. Uhr², S. Modell², H. Künzel², B. Müller-Oerlinghausen¹, M. Bauer^1,3 (¹Berlin; ²München, ³Los Angeles)
Neuroendocrinological changes under lithium augmentation in therapy resistant depression

M. Deuschle¹, B. Hamann¹, M. Colla^1,2, F. Lederbogen¹, I. Heuser^1,2 (¹Mannheim, ²Berlin)
Antidepressive treatment with amitriptyline and paroxetine: effects upon saliva cortisol concentrations

G. Nikisch¹, A. Czernik¹, A. A. Mathé², P. Baumann³ (¹Fulda, ²Stockholm, ³Prilly-Lausanne)
Neuroendocrine, biochemical and pharmacokinetic effects of a long-term treatment with the selective serotonin reuptake inhibitor ( SSRI ) citalopram in major depressive disorder

A. Rodenbeck¹, S. Cohrs¹, W. Jordan¹, E. Rüther¹, G. Hajak^{1, 2} (¹Göttingen, ²Regensburg)
Reduced HPA hyperactivity in primary insomnia by treatment with doxepin

R. Rupprecht, P. Zwanzger, T. Baghai, C. Schüle, R. Ella, F. Padberg (München)
Neuroendocrine effects of repetitive transcranial magnetic stimulation (rTMS)

C. Schüle, T. Baghai, P. Zwanzger, C. Minov, R. Rupprecht (München)
The influence of mirtazapine on HPA axis activity in depressive patients

DO 14:15 – 16:00 Symposium VII Raum A

Animal models in psychiatry
Vorsitzende: D. Rujescu, K.-P. Lesch

K.-P. Lesch (Würzburg)
Genetic dissection of anxiety

S. Hölter (München)
Behavioral and pharmacological characteristics of long-term voluntary alcohol intake and relapse-like drinking

A. Wigger (München)
Two rat lines bred for high (HAB) or low (LAB) anxiety-related behaviour: a novel psychopathological animal model

D. Rujescu (München)
A pharmacological model for psychosis

DO 14:15 – 16:00 Symposium VIII Raum C

New strategies for detection of target proteins for drug development
Vorsitzende: W. Maier, J. Straus

A. Poustka (Bonn)
The use of the microarray-technology in complex disorders

A. Zimmer (Bonn)
Transgenic mouse models as a tool for the identification and validation of novel drug targets

J. Straus (München)
Legal and ethical issues of patenting human DNA sequences

T. Meitinger
Search for susceptibility genes in psychiatric disorders

16:00 – 16:30 Kaffeepause

DO 16:30 – 18:15 Freie Vorträge 2 Raum A

Addiction
Vorsitzende: J. Aldenhoff, U. Zimmermann

J. Böning (Würzburg)
Dopaminergic challenge and addiction related personality-traits

A. Heinz, M. Reimold, G. Schumann, G. Mundle, D. Hermann, R. Bares,
H.-J. Machulla, K. Mann (Tübingen)
Mu-opioid receptor genotype and in vivo availability – association with craving and relapse in alcoholism

P. Netter, C. Toll (Giessen)
Dopaminergic and serotonergic sensitivity in addicted and non-addicted smokers

G. Schumann¹, D. Rujescu², P. Singer³, A. Szegedi³, S. Wiemann⁴, S. Wellek¹,
A. Heinz¹, R. Spanagel¹, K. Mann¹, F. A. Henn¹, N. Dahmen³ (¹Mannheim,
²München,³Mainz, ⁴Heidelberg)
Alcoholism is associated with a NMDA-receptor 2B gene variant

M. N. Smolka¹, G. Lutz, L. G. Schmidt² (¹Berlin, ²Mainz)
Dopaminergic effects of tobacco smoking in probands and alcoholics

U. Zimmermann, K. Spring, S. Kunz, F. Holsboer (München)
Acoustic startle reflex modulation in sons of alcohol-dependent fathers

DO 16:30 – 18:15 Freie Vorträge 3 Raum C

Treatment of depression
Vorsitzende: W. E. Müller, A. Szegedi

M. Adli¹, U. Kießlinger¹, M. Smolka¹, M. Linden¹, P. Neu¹, M. Bauer^1,2 (¹Berlin, ²Los Angeles)
Algorithm-guided treatment of depression compared to standard treatment as usual - results of a randomized controlled trial in depression

H. Jahn, M. Schick, F. Kiefer, P. Kämpf, K. Wiedemann (Hamburg)
A prospective, double-blind, placebo controlled study of metyrapone in the treatment of depression: Preliminary results

A. Plattner, H.-J. Möller, U. Hegerl (München)
The efficacy of combined pharmacotherapy and psychotherapy vs. either modality alone. A review of randomized clinical trials from the 1990’s

A. Szegedi¹, M. J. Müller¹, O. Benkert¹, R. Kohnen² (¹Mainz, ²Nürnberg)
Early improvement during pharmacotherapy with antidepressants as a highly sensitive predictor of later stable response in depression

A. Zobel, P. Falkai, W. Maier (Bonn)
Vagus nerve stimulation in patients with treatment-resistant depression

DO 16:30 – 18:15 Freie Vorträge 4 Raum D

Pathophysiology of schizophrenia
Vorsitzende: E. Gouzoulis-Mayfrank, T. C. Wetter

A. J. Fallgatter¹, W. K. Strik², T. J. Mueller², M. J. Herrmann¹ (¹Würzburg, ²Bern)
Electrophysiological indications for an altered prefrontal response control in schizophrenias

E. Gouzoulis-Mayfrank, J. Daumann, B. Thimm, G. Hensen (Aachen)
Ecstasy (MDMA) use and memory performance

K. Ludewig¹, S. Ludewig², F. X. Vollenweider² (¹Brugg, ²Zürich)
Decreased habituation of the acoustic startle reflex in unmedicated first episode schizophrenia

E. M. Meisenzahl, D. Rujescu, A. Kirner, I. Giegling, N. Kathmann, G. Leinsinger, K. Maag, U. Hegerl, K. Hahn, H.-J. Möller (München)
A genetic polymorphism in interleukin-1ß is associated with altered brain structure in schizophrenia

M. J. Schwarz, H. Krönig, M. Riedel, B. Bondy, M. Ackenheil, N. Müller (München)
Functional polymorphisms of genes coding for Th1 or Th2 cytokines in schizophrenia

T. C. Wetter, T. Bronisch, D. P. Auer (München)
Relative NAA reduction in the frontomesial cortex in patients with residual subtype of schizophrenia

Donnerstag, 27. September 2001

DO 18:30 Mitgliederversammlung der AGNP Raum C

Freitag, 28. September 2001

FR 8:45 – 10:30 Symposium IX Raum D

Immunopathology in psychiatric diseases – pathophysiological and clinical relevance
Vorsitzende: H. Vedder, N. Müller

N. Müller (München)
Psychoneuroimmunology in schizophrenia: Advances for therapy

M. Rothermund (Münster)
S100B blood levels in schizophrenic patients are correlated with negative symptomatology

T. Pollmächer (München)
Low amounts of circulating inflammatory cytokines – do they affect human brain functions?

M. Schedlowski (Essen)
Stress and cellular immune functions in chronic inflammatory diseases

H. Vedder (Marburg)
Production and steroid regulation of cytokines in the course of major depression

FR 8:45 – 10:30 Workshop 1 Raum A

Phase-IV studies in scientific journals
Vorsitzende: R. Kohnen, M. Linden

Diskutanten: M. Gastpar (Essen), H. Helmchen (Berlin), H. J. Möller (München), W. E. Müller (Frankfurt), B. Müller-Oehrlinghausen (Berlin)
FR 8:45 – 10:30 Symposium X Raum C

In vivo neuropharmacology in psychiatric disorders
Vorsitzende: M. Soyka, P. Bartenstein

F. X. Vollenweider (Zürich)
Neuropharmacologic investigations of glutamatergic functions in normals and schizophrenia

T. Rüther (München)
Haloperidol and risperidone induced changes in brain in never medicated schizophrenics as measured by FDG PET

C. G. Schütz (München)
Studying the NMDA and the opioid system in alcohol dependence

A. Heinz (Mannheim)
Carfentanil opioid receptor PET in alcoholism

FR 8:45 – 10:30 Workshop 3 Raum B

The role of glutamatergic neurotransmission for pathogenesis and therapy in chronic alcoholism
Vorsitzende: S. Bleich, M. Gastpar

R. Spanagel (Mannheim)
The role of the glutamatergic system and NO/cGMP signaling in alcohol dependence

S. Bleich (Erlangen)
Homocysteine-induced hippocampal volume reduction in chronic alcoholism – results of volumetric MR imaging study

J. Kornhuber (Erlangen)
The use of NMDA receptor antagonists in addiction therapy

M. Soyka (München)
Glutamatergic mechanisms in alcohol dependence – results from a neuropharmacological challenge study with dextrometorphan and recent experience with acamprosate

Diskutanten: W. Zieglgänsberger (München), K. Mann (Mannheim)

10:30 – 11:00 Kaffeepause

FR 11:00 – 12:45 Symposium XI Raum A

Sensorimotor gating (PPI) in schizophrenia: New vista
Vorsitzende: F. X. Vollenweider, A. Hamm

M. Koch (Bremen)
Recent advances in the neuropharmacology of prepulse inhibition of startle in rats

K. Ludewig (Brugg)
Prepulse inhibition in human – methodological arguments

A. Hamm (Greifswald)
PPI performance in schizophrenia patients: Current status and future issues

F. X. Vollenweider (Zürich)
Brain activation patterns of prepulse inhibition in humans: A [H₂ ¹⁵ O]PET study

FR 11:00 – 12:45 Symposium XII Raum C

Symptom-provocation tests in psychiatric disorders
Vorsitzende: K. Wiedemann, R. Rupprecht

A. Broocks (Lübeck)
Clinical and scientific value of pharmacologic challenge paradigms for the assessment of central serotonin neurotransmission in humans

P. Zwanzger (München)
Treatment with GABAergic drugs improves CCK-4 induced anxiety

H. Jahn (Hamburg)
Functional MRI as a tool to identify neurocircuitries of panic-anxiety

M. Kellner (Hamburg)
Behavioral and endocrine responses to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder

A. Ströhle (München)
Increased nocebo response and CCK-4-hypersensitivity in female patients with panic disorder

FR 11:00 – 12:45 Workshop 2 Raum D

Standards for early interventions in psychiatric disorders
Vorsitzende: H.-J. Möller, J. Fritze

W. Maier (Bonn)
Current status of early recognition and early intervention programmes for schizophrenia

I. Heuser (Berlin)
Current status of early recognition and early intervention programmes for Alzheimer’s disease

H.-J. Möller (München)
Methodical standards for the evaluation of primary prevention in risk probands and treatment of prodromal stages

J. Fritze (Frankfurt)
Ethical framework in early intervention

FR 11:00 – 12:45 Workshop 4 Raum B

Oxidative stress and neurodegenerative disorders
Vorsitzende: A. Eckert, C. Behl

G. Münch (Leipzig)
Anti-inflammatory and pro-energetic antioxidants in the treatment of Alzheimer’s disease

A. Eckert (Frankfurt/M)
Increased oxidative stress-induced cell death in familial Alzheimer’s disease

B. Janetzky (Dresden)
Mitochondria and oxidative stress in Parkinson’s disease

C. Behl (München)
Hormones and antioxidants in nerve cell protection

Diskutanten: W. E. Müller (Frankfurt), P. Riederer (Würzburg), L. Frölich (Frankfurt), M. Lobisch

DO 12:45 – 14:15 Postersitzung II

Grundlagen affektiver Störungen

39. S. Adena, M. Ising, E. Binder, J. Huber, F. Holsboer, S. Modell (München)
    Vulnerability to depression: Evaluation of neuroendocrine, psychometric, and neurophysiological factors in a high risk family
40. H. Bielau¹, N. Gerecke¹, P. Danos¹, D. Krell¹, K. Trübner², S. Diekmann¹,
    H. G. Bernstein¹, B. Bogerts¹, B. Baumann¹ (¹Magdeburg, ²Halle)
    Numbers of dorsal raphe nucleus serotonergic neurons in depressed non-suicidal patients and depressed suicide patients
41. S. Birkmann, A. Schuld, M. Haack, M. Dalal, T. Kraus, T. Pollmächer (München)
    Immunomodulatory properties of low dose dexamethasone – dose and time-of-day effects
42. A. Erfurth, N. Michael, A. Schäfers, C. Raab, M. Reutemann, A. Kersting, V. Arolt (Münster)
    Switching from depression into hypomania or mania: a retrospective study
43. L. Franke, W. Kitzrow, R. Uebelhack, A. Berghöfer, B. Müller-Oerlinghausen (Berlin)
    Platelet 5-HT uptake and poor appetite in patients suffering from major depression
44. J. Gallinat, C. Wernicke, D. Senkowski, W. M. Herrmann, H. Rommelspacher (Berlin)
    Loudness dependence (LD) of auditory evoked potentials is associated with a functional polymorphism in the human serotonin transporter promoter
45. W. Huff, R. Steckel, M. Sitzer (Frankfurt/M)
    Prevention of depression after ischemic stroke – The PreDIS-study
46. M. E. Keck, T. Welt, W. Schmitt, A. Erhardt, A. K. Fischer, M. B. Müller,
    E. Fuchs, B. Czéh (München)
    Chronic psychosocial stress and concomitant repetitive transcranial magnetic stimulation: effects on adult hippocampal neurogenesis
47. M. E. Keck¹, T. Welt¹, M. B. Müller¹, M. Uhr¹, N. Singewald², F. Holsboer¹, R. Landgraf¹ (¹München, ²Innsbruck)
    Attenuation of hyperactivity of the stress hormone system leads to a normalization of hippocampal serotonergic neurotransmission in hyperanxious rats
48. K. Krieger, U. Henning, A. Klimke (Düsseldorf)
    Distinct downregulation of glucocorticoid receptors on blood cells from patients with depressive disorders
49. T. Linka, B. W. Müller, S. Bender, J. Wolstein, H. Conrads, M. Banger (Essen)
    The intensity dependence of the auditory evoked potential in major depression: short term stability and first results of a controlled treatment study
50. R. Mergl, J. Rihl, G. Juckel, P. Tigges, A. Schröter, U. Hegerl (München)
    Kinematical analysis of fine motor dysdiadochokinesia in depressed patients
51. N. Michael, P. Ohrmannn, A. Erfuhrt, M. Wolgast, V. Arolt, W. Heindel,
    B. Pfleiderer (Münster)
    Structural abnormalities related to mood disorders influence voxel composition in localized spectroscopy
52. K. Schlicht, A. Büttner, J. Kuznik, W. Eisenmenger, P. Zill, B. Bondy (München)
    Polymorphisms in genes coding for the 5-HT1A- and 5-HT2A-receptors and the 5-HT-transporter in suicide completers
53. C. Toll, P. Netter (Giessen)
    Predicting subtypes of impulsivity by hormone responses to dopaminergic, noradrenergic, and serotonergic challenge tests
54. P. Zill, T. C. Baghai, P. Zwanzger, C. Schüle, C. Minov, S. Behrens,
    R. Rupprecht, B. Bondy (München)
    Association study of a common polymorphism in the human 5HT1A receptor gene in major depression
55. P. Zill, T. C. Baghai, P. Zwanzger, C. Schüle, C. Minov, S. Behrens,
    R. Rupprecht, B. Bondy (München)
    Association analysis of a polymorphism in the G-protein stimulatory a subunit in patients with major depression
56. P. Zill¹, P. N. Malitas², B. Bondy¹, F. Boufidou², S. Behrens¹, B. E. Alevizos², C. K. Nikalou², G. N. Christodoulou² (¹München, ²Athen)
    Analysis of polymorphisms in the a subunit of the olfactory G-protein G_olf in lithium treated bipolar patients
57. P. Zill, T. C. Baghai, P. Zwanzger, C. Schüle, C. Minov, S. Behrens,
    R. Rupprecht, B. Bondy (München)
    Analysis of polymorphisms in the olfactory G-protein G_olf in major depression
58. P. Zill, T. C. Thomas C., P. Zwanzger, C. Schüle, C. Minov, S. Behrens,
    R. Rupprecht, B. Bondy (München)
    Myo-inositol monophosphatase (IMPA1) and inositol polyphosphate 1-phosphatase (INPP1) gene variants in major depression
59. P. Zill, T. C. Baghai, P. Zwanzger, C. Schüle, C. Minov, S. Behrens,
    R. Rupprecht, B. Bondy (München)
    Polymorphisms in the phospholipase g -1 and b -3 isozymes and major depression

FR 12:45 – 14:15 Postersitzung II

Pharmakologie

60. U. Bonnet, T. Leniger, M. Wiemann (Essen)
    Neuropsychopharmaca and intracellular pH
61. U. Bonnet, D. Büsselberg, M. Wiemann (Essen)
    MAO inhibition is associated with a modest neuronal acidification
62. B. Froestl, B. Steiner, W. E. Müller (Frankfurt)
    Hyperforin affects proteolytic processing of ß-Amyloid precursor protein.
63. M. T. Grauer, F. Holsboer, M.Uhr (München)
    P-glycoprotein affects the ability of amitriptyline, nortriptyline and its metabolites to cross the blood-brain barrier
64. S. Härtter¹, C. Ursing², S. Morita², G. Tybring², C. Von Bahr², M. Christensen², S. Röjdmark², L. Bertilsson² (¹Mainz,² Stockholm-Sweden)
    CYP1A2 phenotyping using orally given melatonin
65. S. Härtter^1,2, G. Tybring², R. Canaparo², T. Friedberg³, H. Weigmann¹, C. Hiemke¹ (¹Mainz, ²Huddinge-Sweden, ³Dundee)
    The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19
66. C. Hiemke, H. Weigmann, S. Härtter, H. Silver (Mainz)
    Fluvoxamine inhibits the metabolism of olanzapine
67. R. Kalisch, S. Wigger, F. Ohl, C. Gössl, M. Czisch, R. Landgraf, D. P. Auer (München)
    BOLD phMRI response to drugs acting at the benzodiazepine (BZP) receptor depends on innate emotionality in rats
68. A. Kastl¹, A. Eckert¹, B. Steiner¹, C. Haass², W. E. Müller¹ (¹Frankfurt, ²Mannheim)
    Impaired calcium regulation in pc12 cells expressing Alzheimer-mutant APP
69. C. Lange-Asschenfeldt , T. Siessmeier, M. Schreckenberger, H-G. Buchholz , K. Mann, C. Hiemke, F. Rösch, P. Bartenstein, G. Gründer (Mainz)
    Lorazepam-induced decrease in EEG alpha-power correlates with decrease in thalamic glucose metabolism: an [¹⁸F]FDG PET study in normal volunteers
70. C. A. Marques¹, B. Steiner¹, C. Haass², W. E. Müller¹, A. Eckert¹ (¹Frankfurt/M., ² München)
    Involvement of caspases in oxidative stress-induced cell death in PC12 cells bearing Alzheimer mutations
71. M. B. Müller, R. Landgraf, F. Holsboer, M. Uhr (München)
    Neuroendocrine regulation in mice deficient for multidrug resistance gene 1-type P-glycoproteins
72. F. Müller-Siecheneder, H-J. Kuß (München)
    Pharmacokinetic interactions of beta-receptor blockers with psychotropic drugs
73. A. Post, T. M. Michaelidis, F. Ohl, F. Holsboer, O. F. X. Almeida (München)
    Mechanisms underlying the protective potential of α-tocopherol (vitamin E) against haloperidol - associated neurotoxicity
74. M. Rosenhagen¹, J. Young², G. Wochnik¹, F. U. Hartl², F. Holsboer¹, T. Rein¹
    (¹München, ²Martinsried)
    Glucocorticoid receptor inhibition by targeting heat shock protein 90
75. J. Sachse¹, S. Härtter¹, H. Weigmann¹, J. Köller², F. Schanz², C. Hiemke¹ (¹Mainz, ² München)
    Automated chromatographic analysis of multiple psychoactive drugs in blood serum or plasma
76. A. Singer, W. E. Müller (Frankfurt)
    Hyperforin alters free intracellular h⁺- and Na⁺-concentration in human platelets
77. L. Steinacher¹, P. Vandel², D. F. Zullino³, C. B. Eap³, M. Brawand³,
    P. Baumann³ (¹Zürich, ²Besançon, ³ Prilly-Lausanne)
    Pharmacokinetic consequences of a carbamazepine augmentation in depressive patients non-responding to citalopram: stereoselective aspects
78. N. Toschi, L. Torner, R. Landgraf, I. D. Neumann (München)
    Improved in vivo efficacy of antisense targeting of the brain prolactin receptor by mRNA secondary structure prediction
79. M. Uhr, F. Holsboer (München)
    P-glycoprotein plays an important role in the uptake of CNS drugs across the blood-brain barrier
80. K. Weber, M. Ackenheil, B. Bondy, S. Behrens, I. Giegling, S. de Jonge,
    D. Rujescu, M. Schäfer (München)
    Influence of the cytochrome P450 2D6 allele 4* genotype on the haloperidol metabolism and clinical parameters

Freitag, 28. September 2001

FR 14:15 – 16:45 Symposium XIII Raum C

Dopamine in Psychiatry. In Honour of Arvid Carlsson
Vorsitzende: F. Holsboer, E. Rüther

N. Matussek (München)
Arvid Carlsson: A great, human, honest scientist

Key note lecture

A. Carlsson (Göteborg)
From dopamine to glutamate in schizophrenia

H. Hippius (München)

Dopamine and clozapine

U. Havemann-Reinecke (Göttingen)
Dopamine and addiction: from ectasy to dependence

T. Pollmächer (München)
Dopamine and sleep

E. Rüther (Göttingen)
Dopamine – a paradigm in psychiatry

H. Ehrenreich (Göttingen)
Beyond dopamine

FR 16:45 – 17:30 Kaffeepause

Freitag, 28. September 2001

FR 17:30 – 18:30 Verleihung des Anna-Monika-Preises Raum C

F. A. Henn (Mannheim) Laudatio
M. Rief-Rehme (Dortmund) Verleihung
Vortrag des Preisträgers
R. S. Duman (New Haven)
A neurotrophic hypothesis of depression

FR 20:00 Burgabend

Mit freundlicher Unterstützung von
Aventis Pharma Deutschland GmbH, Bad Soden am Taunus
Lichtwer Pharma AG, Berlin
Lilly Deutschland GmbH, Bad Homburg
Pfizer GmbH, Karlsruhe

Samstag, 29. September 2001

SA 8:45 – 10:30 Symposium XIV Raum A

New developments in the pharmacotherapy of alcoholism
Vorsitzende: K. Mann, K. Wiedemann

K. Wiedemann (Hamburg)
Modulation of alcohol craving by leptin

F. Kiefer (Hamburg)
A controlled study of naltrexone vs. acamprosate in the relapse prevention of alcoholism

A. Heinz (Mannheim)
Individually adapted therapy of alcoholism

J. Böning (Würzburg)
‘Proof-of-concept’ study in alcohol dependence using the new low-affinity, non-competitive NMDA receptor antagonist nerimexane

K. Mann (Mannheim)
Galanthamin application in alcoholism – effects of cholinergic medication on alcohol intake and relapse

SA 8:45 – 10:30 Symposium XV Raum D

Repetitive transcranial magnetic stimulation (rTMS) and functional imaging in psychiatry
Vorsitzende: G.W. Eschweiler, G. Hajak

A. Sack (Frankfurt/M)
Combining rTMS and fMRI to investigate the functional relevance of neuronal activity

P. Eichhammer (Regensburg)
Cingulate activity as a possible predictor of rTMS treatment outcome

U. Herwig (Ulm)
Neuronavigated transcranial magnetic stimulation according to PET data in major depression

G. W. Eschweiler (Tübingen)
Antidepressive response from prefrontal repetitive transcranial magnetic stimulation (rTMS) and mental work induced cortical oxygenation changes: Combined rTMS and near-infrared spectroscopy (NIRS) studies

J. Höppner (Rostock)
Changes of quantitative EEG parameters after repetitive transcranial magnetic stimulation in patients with depressive disorder

SA 8:45 – 10:30 Symposium XVI Raum C

Imaging in schizophrenia: Recent concepts and therapeutic implications
Vorsitzende: H. Sauer, R. Schlösser

G. J. E. Schmitt (München)
Brain structure changes in schizophrenic patients: Is there an association with the functional state of the striatal dopaminergic synapse? A combined MRI-SPECT-study

F. Schneider (Düsseldorf)
FMRI and emotions in schizophrenia

H. P. Volz (Werneck)
Disturbed attention processes in schizophrenia – evidence from fMRI studies

D. F. Braus (Mannheim)
Differential effects on neuronal viability and function with atypical antipsychotics as opposed to traditional neuroleptics: A MRSI study

R. Schlösser (Mainz)
FMRI-studies of functional connectivity associated with working memory and executive functions in schizophrenia: Effects of pharmacological treatment

10:30 – 11:00 Kaffeepause

Samstg, 29. September 2001

SA 11:00 – 12:45 Freie Vorträge 5 Raum C

Pathophysiology of depression
Vorsitzende: M. Berger, S. Modell

T. Frodl, T. Baghai, C. Schüle, P. Zwanzger, C. Minov, H.-J. Möller, R. Rupprecht, E. M. Meisenzahl (München)
Hippocampal atrophy and hypercortisolaemia in patients with major depression -
a combined investigation in affective disorders

U. Hemmeter, N. Wanner, S. Zechner, V. Hobi, D. R. Heimberg (Basel)
Evaluation of memory processing in depressed patients and healthy subjects by event-related potentials

N. Michael, A. Erfuhrt, P. Ohrmann, M. Wolgast, V. Arolt, W. Heindel,
B. Pfleiderer (Münster)
Metabolic changes in the left anterior cingulum of severely depressed patients
induced by electroconvulsive therapy (ECT)

S. Modell, M. Ising, C. J. Lauer, F. Holsboer (München)
The Munich vulnerability study on affective disorders: Neurobiological and psychometric risk factors

A. Schuld, S. Birkmann, T. Kraus, M. Dalal, M. Haack, T. Pollmächer (München)
Immunomodulatory properties of dexamethasone in depressive patients and healthy controls

B. Weber-Hamann¹, M. Deuschle¹, F. Lederbogen¹, A. Kniest¹, I. Heuser² (¹Mannheim, ²Berlin)
Major depression and the metabolic syndrome

SA 11:00 – 12:45 Freie Vorträge 6 Raum D

Treatment of schizophrenia
Vorsitzende: F. Henn, T. Zetzsche

P. Eichhammer, A. Kharraz, R. Wiegand, G. Hajak (Regensburg)
Pharmacogenetic prediction of response and development of side effects to antipsychotic treatment

G. Gründer¹, I. Vernaleken¹, T. Siessmeier¹, H.-G. Buchholz¹, P. Stoeter¹,
O. Munk², A. Gjedde², F. Rösch¹, P. Bartenstein¹, P. Cumming² (¹Mainz, ²Aarhus)
The modulation of dopamine synthesis in human brain by acute or subchronic haloperidol: a PET study with [¹⁸F]fluoro-DOPA

A. Klimke, K. Krieger, S. Löffler, U. Henning (Düsseldorf)
Transport of the atypical neuroleptic clozapine into promyeloid HL-60 cells

A. Putzhammer, O. Biniasch, H. Koch, M. Perfahl, P. Eichhammer, B. Heindl,
J. Mueller, HE. Klein (Regensburg)
Three-dimensional ultrasonic gait analysis in schizophrenic patients: treatment with conventional neuroleptics vs. treatment with olanzapine

I. Vernaleken, T. Siessmeier, H.-G. Buchholz, C. Hiemke, P. Stoeter, F. Rösch,
P. Bartenstein, G. Gründer (Mainz)
Determination of striatal and thalamic occupancy of D₂-like dopamine receptors by amisulpride in schizophrenic patients: a PET study with [¹⁸F]desmethoxyfallypride

T. Zetzsche, U. Preuss, T. Frodl, H.-J. Möller, E. M. Meisenzahl (München)
Evidence for a correlation between thalamic structures and psychopharmacology in schizophrenia? An in-vivo structural MRI study with 50 schizophrenic patients

SA 11:00 – 12:45 Freie Vorträge 7 Raum A

Anxiety
Vorsitzende: A. Ströhle, A. Broocks

A. Broocks¹, B. Bandelow², K. Koch¹, U. Schweiger¹, F. Hohagen ¹, G. Hajak² (¹Lübeck, ²Göttingen)
The effect of smoking on 5-HT1A receptor responsiveness in patients with panic disorder

M. E. Keck, I. Sillaber, F. Holsboer, F. Ohl (München)
Differential behavioral effects of the selective CRH1 receptor antagonist R121919 in inbred mice-strains differing in their inborn emotionality

S. Ludewig¹, K. Ludewig², MA. Geyer³, D. Hell¹, FX. Vollenweider¹ (¹Zürich, ²Brugg, ³San Diego)
PPI deficit in panic disorder patients correlated with high trait anxiety

A. Ströhle, M. Kellner, F. Holsboer, K. Wiedemann (München)
Anxiolytic activity of atrial natriuretic peptide (ANP) in patients with panic disorder

SA 12:45 – 14:15 Postersitzung III

Therapie affektiver Störungen

81. M. Adli (Berlin)
    Comparison of a systematic treatment algorithm with the standard treatment as usual: results of a randomized controlled study in major depression
82. D. Althaus¹, G. Niklewski ⁴, A. Schmidtke², W. Felber³, U. Hegerl¹
    (¹München, ²Würzburg, ³Dresden, ⁴Nürnberg)
    Improvement of antidepressant pharmacotherapy in the context of an awareness-program carried out in the city of Nuremberg
83. T. C. Baghai, C. Schüle, P. Zwanzger, F. Padberg, R. Ella, C. Minov,
    H. Thoma, R. Rupprecht (München)
    The predictive value of HPA axis dysregulation for nonpharmacological treatment outcome in major depression
84. E. Binder, T. Nickel, H. Künzel, D. Schmid, M. Majer, M. Ising, B. Fuchs, G. Ernst, A. Sonntag, J. Zihl, S. Modell, F. Holsboer (München)
    The Munich antidepressant response signature project
85. B. Bondy¹, P. N. Malitas², P. Zill¹, F. Boufidou², R. R. Engel¹, S. Behrens¹,
    B. E. Alevizos², C. K. Nikolaou², G. N. Christodoulou² (¹München, ²Athen)
    Phospholipase C-g 1 in patients with bipolar disorder: Possible involvement in lithium action and side effects
86. T. Bschor¹, M. Adli¹, C. Baethge¹, M. Ising², M. Uhr², M. Bauer^1,3 (¹Berlin, ²München, ³Los Angeles-USA)
    Lithium augmentation increases ACTH and cortisol response in the combined DEX/CRH test
87. D. Degner¹, R. Grohmann², E. Tönnies¹, S. Kropp³, E. Rüther¹ (¹Göttingen, ²München, ³Hannover)
    Hepatic and pancreatic dysfunctions with newer antidepressant drugs: results from AMSP drug safety program
88. A. Erfurth, N. Michael, V. Arolt (Münster)
    Alternatives to SSRIs in the treatment of bipolar depression
89. G. Holoubek¹, M. Noeldner², W. E. Müller¹ (¹Frankfurt/M, ²Karlsruhe)
    Possible relationship between behavioral and biochemical changes following antidepressant treatment
90. W. P. Kaschka, A. Meyer, K. R. Schier, W. Fröscher (Ravensburg)
    Treatment of pathological crying with Citalopram
91. D. Koethe, M. Haack, D. Hinze-Selch, T. Kraus, A. Schuld, T. Pollmächer (München)
    Body weight and the plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine
92. H.-J. Kuss, C. Schuessler, U. Hegerl (München)
    Paroxetine: Serumconcentrations and therapeutic effects
93. K.W. Lange, O. Tucha, S. Aschenbrenner, P. Eichhammer, A. Putzhammer,
    H. Sartor, H.E. Klein (Regensburg)
    The impact of tricyclic antidepressants and selective serotonin re-uptake inhibitors on handwriting movements of patients with depression
94. M. Linden¹, K. Ludewig¹, T. Munz², W. Dierkes² (¹Berlin, ²Münster)
    Dosage selection and outcome in Venlafaxine routine treatment: Results from a drug utilization observation study in psychiatric outpatients and impatients
95. M. Majer, M. Ising, F. Holsboer, S. Modell, J. Zihl (München)
    Neuropsychological test for the description and prediction of treatment outcome in patients with affective disorders
96. R. Mergl, G. Juckel, T. Frod, F. Müller-Siecheneder, U. Hegerl (München)
    Effects of reboxetine and citalopram on hand motor function in depressed patients
97. . B. Müller, N. Toschi, A. E. Kresse, A. Post, M. E. Keck (München)
    Long-term rTMS increases the expression of BDNF and CCK mRNA, but not NPY mRNA in specific areas of rat brain
98. F. Padberg, P. Zwanzger, P. Mikhaiel, H. Thoma, H. Hampel, H. J. Möller (München)
    Stimulation intensity and antidepressant action of repetitive transcranial magnetic stimulation: a placebo-controlled study
99. B. B. Quednow, K.-U. Kühn, K. Hoenig, W. Maier, M. Wagner (Bonn)
    Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression
100. M. Schick, F. Kiefer, P. Kämpf, J. Arlt, K. Wiedemann, H. Jahn (Hamburg)
     Cell-turnover in the gyrus dentatus in mice is enhanced by metyrapone treatment
101. D. Schmid, K. Held, J. Weikel, H. Künzel, A. Sonntag, A. Steiger (München)
     Changes of DEX-CRH-test results, sleep EEG and nocturnal hormone secretion during therapy of depression by mirtazapine
102. K. D. Vitt¹, R. Schuster¹, D. Melcher¹, J. Fritze² (¹Kiel, ²Frankfurt)
     Analysis of prescription patterns of antidepressants and Lithium: A contribution to quality assurance
103. C. Werner, U. Henning, K. Krieger, A. Klimke (Düsseldorf)
     Changes of serum monoamine metabolites and correlation to prolactin response during clomipramine-challenge
104. P. Zill, T. C. Baghai, S. de Jonge, K. Neumeier, B. Bondy (München)
     Effects of antidepressant treatment on calcium homeostasis and on mRNA levels of the transcription factors c-jun, c-fos, ziff 268 and CREB on immortalized lymphocytes of depressed patients

SA 12:45 – 14:15 Postersitzung III

Sucht

105. I. Anghelescu, C. Klawe, P. Singer, S. Germeyer, A. Szegedi (Mainz)
     Association of the TAQ A1 polymorphism with MAST scores
106. U. Bonnet¹, B. Müller¹, S. Kutscher¹, T. Hashemi¹, M. Specka¹,
     F. M. Leweke², W. Burtscheidt², M. Banger¹ (¹Essen, ²Düsseldorf)
     Treatment of alcohol-withdrawal syndrome with gabapentin – results from a controlled two-centre trial
107. F. Kiefer¹, H. Jahn¹, A. Koester² , R. Reinscheid³ , K. Wiedemann¹ (¹Hamburg, ²Basel, ³Irvine)
     Effects of ethanol on behavior in mutant mice with reduced affinity of the NMDA R1 glycine binding site
108. F. Kiefer, H. Jahn, K. Wolf, M. Schick, T. J. Readler, K. Wiedemann (Hamburg)
     Implication of leptin in the regulation of alcohol craving
109. C. Klawe¹, I. Anghelescu¹, P. Singer¹, C. Fehr^1,2, S. Germeyer³,
     A. Schleicher¹, C. Hiemke¹, N. Dahmen¹, A. Szegedi¹ (¹Mainz, ²Oregon, ³Biberach an der Riss)
     Lower novelty seeking and higher self-directedness scores on TCI in alcohol dependent patients homozygous for the A₁₀ allele of DAT1
110. C. Klawe, I. Anghelescu, P. Singer, B. Schanz (Mainz)
     Prospective study of inpatient violence in a German psychiatric teaching hospital: incidence, patient characteristics and quantification with Staff Observed Aggression Scale (SOAS)
     G. Koller, U. Preuss, M. Bahlmann, P. Zill, M. Soyka, B. Bondy (München)
     No association between metabotropic Glutamate receptors 7 and 8 (mGluR7 and mGluR8) gene polymorphisms and withdrawal seizures and delirium in alcohol dependents.
111. C. Lange-Asschenfeldt, T. Siessmeier, H.-G. Buchholz, C. Klawe,
     A. Szegedi, F. Rösch, P. Bartenstein, G. Gründer (Mainz)
     Benzodiazepine receptor binding in long-term abstinent alcoholics: a PET study with [¹⁸F]fluoroethylflumazenil
112. N. Rollmann¹, E. Davids¹, M. J. Müller¹, M. Burkart¹, E. Regier-Klein¹, A. Szegedi¹ , O. Benkert¹ , W. Maier² (¹Mainz, ²Bonn)
     Similarity of syndrome profiles in alcohol dependence and panic disorder: an exploratory family study
113. G. A. Wiesbeck, H.-G. Weijers, J. Boening (Würzburg)
     Dopaminergic mechanisms and pharmacological relapse prevention in alcohol dependence - results from clinical and animal studies

SA 12:45 – 14:15 Postersitzung III

Gedächtnis / Demenz

114. F. Faltraco, K. Bürger, S. J. Teipel (München), T. Tapiola (Kuopio),
     R. Kohnken (Vernon Hills), H. Arai (Sendai), F. Padberg, H.-J. Möller (München), S. I. Rapoport (Bethesda), P. Davies (Bronx), H. Hampel (München)
     Cerebrospinal fluid tau protein phosphorylated at threonine 231 discriminates between Major Depression and Alzheimer’s disease
115. N. Freymann, D. O. Granath, C. P. Stracke, F. Jessen, J. Reul, R. Heun (Bonn)
     Less is more: better learners activate less during retrieval of learned motor sequences than inferior learners
116. T. Fuchsberger, K. Buerger, S. J. Teipel (München), N. Andreasen (Göteborg), R. Engel, H.-J. Möller (München), K. Blennow (Pitea),
     H. Hampel (München)
     CSF β-amyloid_1-42 but not total tau predicts conversion from mild cognitive impairment into Alzheimer’s disease
117. C. Kirsch, G. P. Eckert, W. E. Müller (Frankfurt/M)
     Effects of lovastatin treatment on brain cholesterol levels in normal and apoE knock-out mice
118. A. Post, N. Ackl, M. Uhr, M. E. Keck, A. Sonntag, F. Holsboer (München)
     Cerebrospinal fluid levels of the soluble amyloid precursor protein in patients with mild cognitive impairment and different forms of dementia: a diagnostic marker ?
119. H.-J. Schewe, R. Uebelhack, K. Vohs (Berlin)
     Saccadic eye movements in dementia, major depression and healthy controls
120. U. Schmitt, C. Hiemke (Mainz)
     Memory impairment by GABA transporter inhibition in rats
121. K. Schüssel¹, S. Leutner¹, N. J. Cairns², A. Eckert¹, W. E. Müller¹ (¹Frankfurt, ²London)
     Increased activities of antioxidant enzymes in brains from Alzheimer’s disease patients
122. B. Hagen, W. D. Oswald, R. Rupprecht, K. G. Gaßmann (Erlangen)
     Development of mortality risks
123. B. Hagen, W.D. Oswald, R. Rupprecht (Erlangen)
     Risk factors for a loss of independent living
124. W.D. Oswald, B. Hagen, R. Rupprecht (Erlangen)
     Long-term effects of a combined memory and psychomotor training in old age
125. R. Rupprecht, W. D. Oswald, B. Hagen, K.-C. Steinwachs (Erlangen)
     Early detection of a dementia

Dank für die finanzielle Unterstützung des 22. AGNP-Symposiums

gilt den Firmen

Aventis Pharma Deutschland GmbH, Bad Soden
am Taunus
Bayer Vital GmbH, Leverkusen
Bristol-Myers Squibb GmbH, München
Lichtwer Pharma AG, Berlin
Lilly Deutschland GmbH, Bad Homburg
Organon GmbH, Oberschleißheim
Pfizer GmbH, Karlsruhe
Pharmacia GmbH, Erlangen
Dr. Willmar Schwabe Arzneimittel GmbH & Co., Karlsruhe
SmithKline Beecham Pharma GmbH, München